What is Zacks Small Cap's Estimate for TELO Q1 Earnings?

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO - Free Report) - Zacks Small Cap decreased their Q1 2025 earnings estimates for shares of Telomir Pharmaceuticals in a research report issued to clients and investors on Wednesday, February 5th. Zacks Small Cap analyst B. Sorensen now expects that the company will earn ($0.10) per share for the quarter, down from their prior forecast of ($0.06). The consensus estimate for Telomir Pharmaceuticals' current full-year earnings is ($0.40) per share. Zacks Small Cap also issued estimates for Telomir Pharmaceuticals' Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.40) EPS, Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.36) EPS.

Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.05).

Telomir Pharmaceuticals Stock Up 2.4 %

Telomir Pharmaceuticals stock traded up $0.11 during trading hours on Friday, hitting $4.48. 53,821 shares of the company traded hands, compared to its average volume of 110,836. The firm's 50-day simple moving average is $4.76 and its two-hundred day simple moving average is $4.83. The firm has a market cap of $133.18 million and a P/E ratio of -7.67. Telomir Pharmaceuticals has a 1-year low of $3.11 and a 1-year high of $20.72.

Hedge Funds Weigh In On Telomir Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Barclays PLC raised its holdings in shares of Telomir Pharmaceuticals by 325.1% during the third quarter. Barclays PLC now owns 7,018 shares of the company's stock valued at $45,000 after acquiring an additional 5,367 shares during the period. Geode Capital Management LLC grew its position in Telomir Pharmaceuticals by 259.8% during the 3rd quarter. Geode Capital Management LLC now owns 238,737 shares of the company's stock worth $1,533,000 after purchasing an additional 172,382 shares in the last quarter. State Street Corp raised its stake in Telomir Pharmaceuticals by 99.1% during the 3rd quarter. State Street Corp now owns 36,094 shares of the company's stock valued at $232,000 after purchasing an additional 17,967 shares during the period. Suncoast Equity Management lifted its holdings in shares of Telomir Pharmaceuticals by 109.9% in the third quarter. Suncoast Equity Management now owns 51,194 shares of the company's stock valued at $329,000 after purchasing an additional 26,803 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Telomir Pharmaceuticals by 327.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 46,406 shares of the company's stock valued at $191,000 after buying an additional 35,556 shares in the last quarter.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.